Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the ...

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Interim analysis shows misetionamide is very well tolerated in combination with gemcitabine; rates of confirmed response, stable disease, and progression-free survival compare favorably with ...

Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to be presented on Monday, June 2 between ...

BERWYN, PA, June 13, 2025 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. ("Panavance” or the "Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology ...

ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profilingPoster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / ACCESS ...

This update will be presented as part of the OPERA-01 trial-in-progress poster at the American Society ... our OPERA-01 and OPERA-02 pivotal trials with top-line data from OPERA-01 anticipated ...

From the practical wisdom of emphasising exercise to improve survival in colon cancer to the association of glucagon-like ...

Discover why HPV vaccination rates lag behind despite preventing cervical cancer. Learn the facts about this life-saving ...